These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 29882591)
1. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review. Tomaselli Muensterman E; Tisdale JE Pharmacotherapy; 2018 Aug; 38(8):813-821. PubMed ID: 29882591 [TBL] [Abstract][Full Text] [Related]
2. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938 [TBL] [Abstract][Full Text] [Related]
3. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028 [TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Haddad PM; Anderson IM Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926 [TBL] [Abstract][Full Text] [Related]
5. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Tisdale JE; Jaynes HA; Kingery JR; Mourad NA; Trujillo TN; Overholser BR; Kovacs RJ Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):479-87. PubMed ID: 23716032 [TBL] [Abstract][Full Text] [Related]
6. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796 [TBL] [Abstract][Full Text] [Related]
7. Risk factors for QTc-prolongation: systematic review of the evidence. Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V Int J Clin Pharm; 2017 Feb; 39(1):16-25. PubMed ID: 28012118 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Tisdale JE; Jaynes HA; Kingery JR; Overholser BR; Mourad NA; Trujillo TN; Kovacs RJ Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):381-90. PubMed ID: 24803473 [TBL] [Abstract][Full Text] [Related]
9. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes. Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411 [TBL] [Abstract][Full Text] [Related]
10. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. Hasnain M; Vieweg WV CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784 [TBL] [Abstract][Full Text] [Related]
12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V; Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268 [TBL] [Abstract][Full Text] [Related]
13. Personalized, intuitive & visual QT-prolongation monitoring using patient-specific QTc threshold with pseudo-coloring and explainable AI. Alahmadi A; Davies A; Vigo M; Jay C J Electrocardiol; 2023; 81():218-223. PubMed ID: 37837739 [TBL] [Abstract][Full Text] [Related]
14. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients. Shao W; Ayub S; Drutel R; Heise WC; Gerkin R J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476 [TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT Interval Prolongation in the Intensive Care Unit. Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523 [TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Tisdale JE Can Pharm J (Ott); 2016 May; 149(3):139-52. PubMed ID: 27212965 [TBL] [Abstract][Full Text] [Related]
17. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study. Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480 [TBL] [Abstract][Full Text] [Related]
18. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Mayet S; Gossop M; Lintzeris N; Markides V; Strang J Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918 [TBL] [Abstract][Full Text] [Related]
19. Navigating the Minefield of QTc Interval-Prolonging Therapy in Nursing Facility Residents. Zarowitz BJ; Tisdale JE J Am Geriatr Soc; 2019 Jul; 67(7):1508-1515. PubMed ID: 30747995 [TBL] [Abstract][Full Text] [Related]
20. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK Ther Adv Psychopharmacol; 2014 Jun; 4(3):130-8. PubMed ID: 25057346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]